Liu Yan, Li Hui, Li Xiang, Zhang Tingting, Zhang Yang, Zhu Jing, Cui Heran, Li Rixin, Cheng Ying
Translational Oncology Research Lab Jilin Province, Jilin Provincial Key Laboratory of Molecular Diagnostics for Lung Cancer, Jilin Cancer Hospital, Changchun, 130012, China.
Department of Medical Thoracic Oncology, Jilin Cancer Hospital, Changchun, 130012, China.
Heliyon. 2024 Jul 4;10(13):e34013. doi: 10.1016/j.heliyon.2024.e34013. eCollection 2024 Jul 15.
Phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha mutations are associated with drug resistance and prognosis in lung cancer; however, the consistency and clinical value of mutations between tissue and liquid samples are unknown.
Circulating tumor DNA (ctDNA) and matched tumor tissue samples from 405 advanced lung cancer patients were collected at Jilin Cancer Hospital between 2018 and 2022, and the mutation status was sequenced using next-generation sequencing based on a 520 gene panel. The viability of different mutant lung cancer cells was detected using MTT assay.
mutations were detected in 46 (5.68 %) of 810 lung cancer samples, with 21 (5.19 %) of 405 plasma samples and 25 (6.17 %) of 405 matched tissues. p.Glu542Lys, p.Glu545Lys, and p.His1047Arg were the most common mutation types of in both the ctDNA and tissue samples. The concordance of mutations was 97.53 % between ctDNA and matched tissues (kappa: 0.770, = 0.000), with sensitivity/true positive rate of 72.0 %, specificity/true negative rate of 99.2 %, and negative predictive value and positive predictive value of 0.982 and 0.857, respectively (AUC = 0.856, = 0.000). Furthermore, the concordance of mutations was 98.26 % in lung adenocarcinoma and 96.43 % in lung squamous cell carcinoma. and were the most common concomitant mutations in ctDNA and tissues. Patients with mutations showed a high tumor mutational burden (TMB) ( < 0.001) and a significant correlation between bTMB and tTMB (r = 0.5986, P = 0.0041). For the tmut/ctDNA mut cohort, pathways alteration was associated with male sex ( = 0.022), old age ( = 0.007), and smoking ( = 0.001); tmut/ctDNA wt patients harbored clinicopathological factors of adenocarcinoma stage IV, with low PS score (≤1) and TMB.
This study showed that ctDNA is highly concordant and sensitive for identifying mutations, suggesting that mutation detection in liquid samples may be an alternative clinical practice for tissues.
磷脂酰肌醇-4,5-二磷酸3-激酶催化亚基α突变与肺癌的耐药性和预后相关;然而,组织样本和液体样本之间突变的一致性及临床价值尚不清楚。
2018年至2022年期间,在吉林省肿瘤医院收集了405例晚期肺癌患者的循环肿瘤DNA(ctDNA)和配对的肿瘤组织样本,并基于520个基因的检测板,采用二代测序对突变状态进行测序。使用MTT法检测不同突变型肺癌细胞的活力。
在810份肺癌样本中,46份(5.68%)检测到突变,其中405份血浆样本中有21份(5.19%),405份配对组织中有25份(6.17%)。p.Glu542Lys、p.Glu545Lys和p.His1047Arg是ctDNA和组织样本中最常见的突变类型。ctDNA与配对组织之间突变的一致性为97.53%(kappa值:0.770,P = 0.000),敏感性/真阳性率为72.0%,特异性/真阴性率为99.2%,阴性预测值和阳性预测值分别为0.982和0.857(AUC = 0.856,P = 0.000)。此外,肺腺癌中突变的一致性为98.26%,肺鳞癌中为96.43%。 和 是ctDNA和组织中最常见的伴随突变。携带 突变的患者显示出较高的肿瘤突变负荷(TMB)(P < 0.001),且bTMB与tTMB之间存在显著相关性(r = 0.5986,P = 0.0041)。对于tmut/ctDNA mut队列, 通路改变与男性(P = 0.022)、老年(P = 0.007)和吸烟(P = 0.001)相关;tmut/ctDNA wt患者具有IV期腺癌、低PS评分(≤1)和TMB的临床病理特征。
本研究表明,ctDNA在识别 突变方面具有高度一致性和敏感性,提示液体样本中的 突变检测可能是组织检测的一种替代临床实践。